The CAMEO-SEMA trial, published in Nature Medicine on November 8, 2026, found lower heart-filling pressure during exercise with semaglutide, a medicine that copies a gut-hormone signal. Participants had obesity and one form of heart failure. That offers a possible explanation for earlier symptom improvements. It does not establish longer survival or mean heart failure has gone away.

The condition is HFpEF, or heart failure with preserved ejection fraction: the heart's squeeze stays near normal, but it fills at high pressure. A normal-looking squeeze doesn't mean the heart is working comfortably.

What question did the CAMEO-SEMA trial ask?

As of November 12, 2026, the day this article was written, Nature Medicine's November 8 report adds a direct pressure measurement to the semaglutide evidence.

The question was whether semaglutide changes the pressure problem itself. Earlier STEP-HFpEF results concerned symptoms, daily limitations and walking distance. Those matter to patients. Measuring pressure asks a different question about what is happening inside the circulation.

This also differs from the SELECT trial, which counted serious heart and blood-vessel events in people with established artery disease. The broader semaglutide and heart health guide separates those questions.

Who took part, and for how long?

Researchers at Mayo Clinic studied 81 adults over 52 weeks. Participants were assigned by chance to semaglutide or placebo, a matching treatment without the active medicine. Participants and investigators did not know the assignment.

The trial record, NCT05371496, required adults aged at least 18 with obesity and symptomatic heart failure. Their BMI, a measure relating weight to height, had to be at least 30. Their ejection fraction, the share of blood pumped out with each beat, had to be at least 50%.

People with a heart-failure hospitalization in the previous 30 days were excluded. So were people whose breathlessness was mainly caused by certain other heart or lung conditions. These results describe a selected group, not everyone who feels short of breath.

Both groups received lifestyle counseling. The study's semaglutide target was 2.4 mg weekly; an individual's actual dose belongs with their prescriber.

How was heart-filling pressure measured?

Researchers used right-heart catheterization: a thin tube passed through a vein allows pressure measurements while a person exercises.

The main measurement was pulmonary artery wedge pressure, an estimate of pressure on the heart's left side as it fills. High pressure here reflects congestion, or blood backing up toward the lungs. This is different from a blood-pressure reading taken with an arm cuff.

The main comparison was the change during low-intensity exercise after a year.

What did the pressure results show?

The 2026 Nature Medicine report estimated an exercise-pressure difference of 10.6 mmHg lower with semaglutide than placebo. The unit mmHg means millimeters of mercury, a way of measuring pressure.

Measurement at 52 weeks Semaglutide Placebo
Average change in exercise filling pressure −9.8 mmHg +0.9 mmHg
Met the study's pressure-based remission definition 53.7% 7.4%

The estimated resting-pressure difference also favored semaglutide, by 7.1 mmHg. These are study-group findings, not a prediction for one person's response.

What does “remission” mean here?

It means normal filling pressures at rest and during exercise under the trial's definition. The registry specifies pressure below 15 mmHg at rest and below 25 mmHg during exercise.

That is a meaningful change in a test result. It does not establish that the underlying condition is permanently gone. Nor does it establish what happens after semaglutide stops.

A pressure threshold cannot decide whether someone can stop a heart medicine. Any change to heart-failure treatment belongs with the cardiologist managing that person's care.

What did the cardiac MRI substudy add?

A companion Nature Medicine paper, also published November 8, 2026, examined heart scans in 49 participants: 33 assigned semaglutide and 16 placebo.

Cardiac MRI uses magnetic fields to make detailed pictures of the heart. Scans were taken at the start and at 52 weeks. The main scan measurement was left atrial reservoir strain: how much the upper-left chamber stretches while holding incoming blood.

The semaglutide group had a better result on that measure and on a measure of how the lower-left chamber fills. Those changes tracked with lower exercise pressure.

This provides a possible explanation for the pressure findings. Changes moving together do not prove that one caused the other. And these were participants from the same trial, not a second independent test of treatment.

What about side effects and the new FDA warning?

Lower heart pressure does not remove semaglutide's known risks. The Wegovy prescribing information, marked “Revised: 06/2026,” lists nausea, vomiting, diarrhea and constipation among common side effects. Its boxed warning, the label's most prominent kind, concerns thyroid C-cell tumors seen in rodents; whether Wegovy causes them in humans is unknown. Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2).

Its Medication Guide directs people to stop using Wegovy and call their healthcare provider right away for severe stomach pain that will not go away. This applies with or without nausea or vomiting; pain may reach the back. It can signal pancreatitis, inflammation of the pancreas.

As of November 12, 2026, the day this article was written, FDA's November 9 safety communication requires new warnings across GLP-1 medicines, drugs that copy a gut-hormone signal. The concern is a potential increased risk of NAION, a rare eye condition involving reduced blood flow to the nerve carrying sight signals. It can cause permanent sight loss. FDA directs patients to contact their healthcare professional right away for sudden, painless vision loss, missing or blurred vision, or distorted colors.

An 81-person trial cannot settle rare risks like this.

Where does tirzepatide fit?

Tirzepatide is a different medicine with its own heart-failure study. SUMMIT's trial record names worsening heart-failure events and death from heart or blood-vessel causes among its main outcomes.

CAMEO-SEMA did not compare semaglutide with tirzepatide. Results from separate trials cannot rank them, establish a dose conversion, or justify switching between them. The semaglutide for heart failure overview covers the wider clinical discussion.

What changes for a prescription, and what comes next?

The new findings add evidence about pressure and heart function. They do not establish fewer hospitalizations or deaths, or a new labeled use. Wegovy's June 2026 label does not list heart failure as an indication, meaning a specified use on the label.

Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications. These are different from FDA-approved products: the formulations offered here are not FDA-approved. FDA explains that it does not verify compounded medications' safety, effectiveness or quality before marketing. A trial of a manufactured study medicine cannot establish the same outcomes for a compounded preparation.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If you have heart failure, tell the reviewing provider about it, and keep your cardiologist informed about any new medicine.

The next questions are whether pressure improvements last, how they relate to everyday symptoms, and whether larger studies find fewer serious heart-failure events. A year of pressure measurements is useful evidence. It is not the whole course of someone's heart disease.